Perioperative FOLFOX4 chemotherapy and surgery versus surgery alone for resectable liver metastases from colorectal cancer (EORTC 40983): long-term results of a randomised, controlled, phase 3 trial, Lancet Oncol, vol.14, p.24120480, 2013. ,
Adjuvant therapy with fluorouracil and oxaliplatin in stage II and elderly patients (between ages 70 and 75 years) with colon cancer: subgroup analyses of the Multicenter International Study of Oxaliplatin, Fluorouracil, and Leucovorin in the Adjuvant Treatment of Colon Cancer trial, J Clin Oncol Off J Am Soc Clin Oncol, vol.30, pp.3353-3360, 2012. ,
Leucovorin and fluorouracil with or without oxaliplatin as first-line treatment in advanced colorectal cancer, J Clin Oncol Off J Am Soc Clin Oncol, vol.18, pp.2938-2947, 2000. ,
Factors affecting sensitivity to antitumor platinum derivatives of human colorectal tumor cell lines, Cancer Chemother Pharmacol, vol.62, pp.577-584, 2008. ,
Organic cation transporters are determinants of oxaliplatin cytotoxicity, Cancer Res, vol.66, pp.8847-8857, 2006. ,
Cisplatin and oxaliplatin, but not carboplatin and nedaplatin, are substrates for human organic cation transporters (SLC22A1-3 and multidrug and toxin extrusion family), J Pharmacol Exp Ther, vol.319, pp.879-886, 2006. ,
Significance of organic cation transporter 3 (SLC22A3) expression for the cytotoxic effect of oxaliplatin in colorectal cancer, Drug Metab Dispos Biol Fate Chem, vol.36, pp.2299-2306, 2008. ,
Oxaliplatin activity in selected and unselected human ovarian and colorectal cancer cell lines, Biochem Pharmacol, vol.76, pp.53-61, 2008. ,
High expression of organic anion transporter 2 and organic cation transporter 2 is an independent predictor of good outcomes in patients with metastatic colorectal cancer treated with FOLFOX-based chemotherapy, Am J Cancer Res, vol.4, pp.528-536, 2014. ,
Organic cation transporter 2 and tumor budding as independent prognostic factors in metastatic colorectal cancer patients treated with oxaliplatin-based chemotherapy, Int J Clin Exp Pathol, vol.7, pp.204-212, 2014. ,
Increased levels of copper efflux transporter ATP7B are associated with poor outcome in colorectal cancer patients receiving oxaliplatin-based chemotherapy, Int J Cancer J Int Cancer, vol.124, pp.2905-2910, 2009. ,
Immunohistochemical analysis revealed CD34 and Ki67 protein expression as significant prognostic factors in colorectal cancer, Med Oncol Northwood Lond Engl, vol.27, pp.304-309, 2010. ,
EGFR expression as a predictor of survival for first-line chemotherapy plus cetuximab in patients with advanced non-small-cell lung cancer: analysis of data from the phase 3 FLEX study, Lancet Oncol, vol.13, issue.11, pp.70318-70325, 2012. ,
Research electronic data capture (REDCap)-a metadata-driven methodology and workflow process for providing translational research informatics support, J Biomed Inform, vol.42, pp.377-381, 2009. ,
Group sequential methods with applications to clinical trials, 2000. ,
, Oxaliplatin Transporters and FOLFOX-4 Adjuvant Chemotherapy PLOS ONE, 2016.
Statistical evaluation of a biomarker, Anesthesiology, vol.112, pp.1023-1040, 2010. ,
Sample Size Determination for Some Common Nonparametric Tests, J Am Stat Assoc, vol.82, pp.645-647, 1987. ,
Do multiple outcome measures require p-value adjustment, BMC Med Res Methodol, vol.2, issue.8, 2002. ,
A power primer, Psychol Bull, vol.112, pp.155-159, 1992. ,
Genetically modified mouse models for oral drug absorption and disposition, Curr Opin Pharmacol, vol.13, pp.853-858, 2013. ,
Human organic cation transporters 1 (SLC22A1), 2 (SLC22A2), and 3 (SLC22A3) as disposition pathways for fluoroquinolone antimicrobials, Antimicrob Agents Chemother, vol.57, pp.2705-2711, 2013. ,
Organic cation transporter 1 (OCT1/mOct1) is localized in the apical membrane of Caco-2 cell monolayers and enterocytes, Mol Pharmacol, vol.84, pp.182-189, 2013. ,
Drug specificity and intestinal membrane localization of human organic cation transporters (OCT), Biochem Pharmacol, vol.70, pp.1851-1860, 2005. ,
Reduced hepatic uptake and intestinal excretion of organic cations in mice with a targeted disruption of the organic cation transporter 1 (Oct1 [Slc22a1]) gene, Mol Cell Biol, vol.21, pp.5471-5477, 2001. ,
Taste of a pill: organic cation transporter-3 (OCT3) mediates metformin accumulation and secretion in salivary glands, J Biol Chem, vol.289, pp.27055-27064, 2014. ,
Irinotecan combined with fluorouracil compared with fluorouracil alone as first-line treatment for metastatic colorectal cancer: a multicentre randomised trial, Lancet Lond Engl, vol.355, pp.1041-1047, 2000. ,
Irinotecan plus fluorouracil and leucovorin for metastatic colorectal cancer. Irinotecan Study Group, N Engl J Med, vol.343, pp.905-914, 2000. ,
Human organic cation transporter 1 is expressed in lymphoma cells and increases susceptibility to irinotecan and paclitaxel, J Pharmacol Exp Ther, vol.341, pp.16-23, 2012. ,
Morphine is a substrate of the organic cation transporter OCT1 and polymorphisms in OCT1 gene affect morphine pharmacokinetics after codeine administration, Biochem Pharmacol, vol.86, pp.666-678, 2013. ,
Proton pump inhibitors inhibit metformin uptake by organic cation transporters (OCTs), PLoS ONE, vol.6, p.22163, 2011. ,
Investigating the role of nucleoside transporters in the resistance of colorectal cancer to 5-fluorouracil therapy, Cancer Chemother Pharmacol, vol.71, pp.817-823, 2013. ,
Metastatic colorectal cancer: from improved survival to potential cure, Oncology, vol.78, pp.237-248, 2010. ,
Effect of surgical margin status on survival and site of recurrence after hepatic resection for colorectal metastases, Ann Surg, vol.241, pp.715-722, 2005. ,